SpringWorks Therapeutics Inc

Common Name

SpringWorks Therapeutics

Country

United States

Sector

Healthcare

Industry

Biotechnology

Employees

368

Ticker

SWTX

Exchange

NASDAQ/NGS

Website

www.springworkstx.com

Description

SpringWorks Therapeutics, Inc. is a biopharmaceutical company committed to advancing innovative medicines for rare diseases. The company focuses on targeting patient populations where unmet needs are ... Show more

Financial Statements of SpringWorks Therapeutics

Below are the financial statements of SpringWorks Therapeutics, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Income Statement (as reported) Balance Sheet (as reported)

All figures in thousands of USD	2024	2023
Current assets	—	—
Cash and cash equivalents	69,751^a	176,053^a
Marketable securities	238,234^a	303,149^a
Accounts receivable, net	46,238^a	5,930^a
Inventory	10,212^a	3,103^a
Prepaid expenses and other current assets	16,030^a	12,677^a
Total current assets	380,465^a	500,912^a
Assets	—	—
Long-term marketable securities	153,933^a	183,386^a
Property and equipment, net	19,680^a	17,943^a
Operating lease right-of-use assets	6,979^a	6,144^a
Equity method investment	4,190^a	1,955^a
Restricted cash	624^a	613^a
Other assets	21,405^a	14,835^a
Total assets	587,276^a	725,788^a
Current liabilities	—	—
Accounts payable	12,248^a	7,396^a
Accrued expenses	86,012^a	65,569^a
Operating lease liabilities, current	1,730^a	1,061^a
Deferred revenue, current	0^a	4,144^a
Total current liabilities	99,990^a	78,170^a
Liabilities and stockholders’ equity	—	—
Operating lease liabilities, long-term	6,182^a	5,996^a
Deferred revenue, long-term	0^a	15,403^a
Total liabilities	106,172^a	99,569^a
Stockholders’ equity	—	—
Preferred stock	0^a	0^a
Common stock	7^a	7^a
Additional paid-in capital	1,646,537^a	1,524,196^a
Accumulated deficit	-1,153,165^a	-895,034^a
Treasury stock, at cost	-12,579^a	-4,141^a
Accumulated other comprehensive income (loss)	304^a	1,191^a
Total stockholders’ equity	481,104^a	626,219^a
Total liabilities and stockholders’ equity	587,276^a	725,788^a

Verified Sources Behind SpringWorks Therapeutics’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore SpringWorks Therapeutics’s data sources below and access millions more through our Disclosure Search.

a. SpringWorks Therapeutics's Annual Report 2025

Trace every data point back to SpringWorks Therapeutics’s disclosures

Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.

Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

At Tracenable, we're exploring the launch of real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?

Explore Peer Companies

Welcome Back to Tracenable

Sign in to your account

SpringWorks Therapeutics Inc

Financial Statements of SpringWorks Therapeutics

Verified Sources Behind SpringWorks Therapeutics’s Financial Fundamentals Data

Access Standardized Financial Statements within Minutes of Disclosure

Explore Peer Companies

TG Therapeutics Inc

Vericel Corp

Blueprint Medicines Corp

Immunovant Inc

Ultragenyx Pharmaceutical Inc

Cytokinetics Inc